MSD

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster

Retrieved on: 
Lunedì, Febbraio 26, 2024
Health Technology, COVID-19, Technology, Finance, Pharmaceutical, Professional Services, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, MSD, Multimedia, Messenger, Coronavirus, Vaccine, African swine fever virus, University, Malaria, Element, Jenner Institute, COVID, University of Oxford, Big data, Deep learning, DNA

View the full release here: https://www.businesswire.com/news/home/20240219023333/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
    From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer).
  • Photo credit: Baseimmune
    “We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital.
  • This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
  • By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.

Beyond Type 1 Announces New Board Members and Executive Team

Retrieved on: 
Giovedì, Febbraio 15, 2024
MSD, Type 1, Diabetes, SAN, Marketing, Yahoo!, 1Life Healthcare, American Heart Association, Education, The Recording Academy, Growth, Empowerment, Sports marketing, Activision Blizzard, Beyond, Sport, ESPN, Diagnosis, Priyanka Chopra, BDT, MGM Resorts International, Management

SAN MATEO, Calif., Feb. 15, 2024 /PRNewswire/ -- Beyond Type 1 today announced three new board members and four new executives to lead the organization as it grows its program, community, and partner network in 2024.

Key Points: 
  • "Their diverse expertise and unwavering dedication to serving people with diabetes will be instrumental in driving our initiatives forward.
  • They each share an important passion and personal connection to the work of Beyond Type 1."
  • The new members of Beyond Type 1's Board of Directors comprise a diverse set of senior leaders across multiple industries who are all united in their commitment to fighting diabetes.
  • Beyond Type 1 also welcomed four accomplished executives to its leadership team , bringing decades of combined expertise across healthcare, technology, marketing, creative, and operations.

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Martedì, Febbraio 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, MSD, Therapy, Roche, Infliximab, Pfizer, AstraZeneca, Senior, Immune-mediated inflammatory diseases, Merck, Schering-Plough, CMO, Neutrophil, Research and development, Adalimumab, Inflammation, Belatacept, Leiden University, Stallergenes Greer, Bristol Myers Squibb, Abatacept, Rheumatoid arthritis, Hidradenitis suppurativa, Merck & Co., Patient, Pierre Fabre, Biology, Development, Pharmaceutical industry

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

SP Plus Stockholders Approve Merger With Metropolis Technologies

Retrieved on: 
Lunedì, Febbraio 12, 2024
Slate, MSD, SP, SP Plus Corporation, Plan, Metropolis, Special, Second request, Willkie Farr & Gallagher, DOJ, BDT, Agreement, Sub

CHICAGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- SP Plus Corporation (“SP+”) (NASDAQ: SP) today announced that at its special meeting of stockholders held on February 9, 2024 (the “Special Meeting”), SP+ stockholders voted to approve the previously announced Agreement and Plan of Merger, dated as of October 4, 2023, by and among Metropolis Technologies, Inc. (“Metropolis”), Schwinger Merger Sub Inc., a direct, wholly owned subsidiary of Metropolis (“Merger Sub”) and SP+ (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into SP+ (the “Merger”), with SP+ surviving the Merger as a wholly owned subsidiary of Metropolis.

Key Points: 
  • CHICAGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- SP Plus Corporation (“SP+”) (NASDAQ: SP) today announced that at its special meeting of stockholders held on February 9, 2024 (the “Special Meeting”), SP+ stockholders voted to approve the previously announced Agreement and Plan of Merger, dated as of October 4, 2023, by and among Metropolis Technologies, Inc. (“Metropolis”), Schwinger Merger Sub Inc., a direct, wholly owned subsidiary of Metropolis (“Merger Sub”) and SP+ (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into SP+ (the “Merger”), with SP+ surviving the Merger as a wholly owned subsidiary of Metropolis.
  • Under the terms of the Merger Agreement, SP+ stockholders will be entitled to receive $54.00 per share in cash, without interest and subject to any required tax withholding, at the closing of the Merger.
  • Approval by SP+’s stockholders satisfies one of the conditions necessary for completion of the Merger.
  • SP+ and Metropolis will continue to cooperate fully with the DOJ in its review.

MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE

Retrieved on: 
Giovedì, Febbraio 8, 2024
MSD, AI, Machine learning, Patient, Vector Institute, Vector, Artificial intelligence, MRK, Deep learning, Health, Data science, Organization, Pharmaceutical industry

This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and expertise in AI and engage with its robust and thriving ecosystem to drive innovation in healthcare.

Key Points: 
  • This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and expertise in AI and engage with its robust and thriving ecosystem to drive innovation in healthcare.
  • As such, Merck Canada will have the opportunity to tap into Vector Institute's extensive network of AI researchers, engineers, and startups.
  • "We are excited about the opportunities that our collaboration with the Vector Institute brings to Merck Canada.
  • Together with Vector, Merck's strong commitment to innovation in health will help realize AI capabilities that can be life-changing for patients," said Tony Gaffney, President and CEO, Vector Institute.

Evaxion Announces Closing of $15 Million Public Offering

Retrieved on: 
Martedì, Febbraio 6, 2024
MSD, Security (finance), ADS, GHI, Prospectus, American depositary receipt, Merck, 3rd Floor, Sale, Merck & Co., Form

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering.

Key Points: 
  • MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to the Company from the offering were $15 million before deducting the placement agent's fees and other offering expenses payable by the Company.
  • The offering was made only by means of a prospectus, which is part of the effective registration statement.

Merck Animal Health to Acquire Elanco’s Aqua Business

Retrieved on: 
Lunedì, Febbraio 5, 2024
Biotechnology, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Fitness & Nutrition, Science, Veterinary, Clinical Trials, MSD, Schering-Plough, Elanco, PIT, Vaki, ELAN, MRK, Goldman Sachs, Covington & Burling, Water, Vaccine, Acquisition, Merck, Merck & Co., LLP, Aquaculture

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

Key Points: 
  • Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.
  • “We are excited for the acquisition of Elanco’s aqua products, solutions as well as the capabilities and expertise the team brings to our business,” said Rick DeLuca, president, Merck Animal Health.
  • The addition of this innovative portfolio of cold water and warm water aqua products across vaccines, anti-parasitic treatments, water supplements and nutrition, will establish Merck Animal Health as a leader in aqua.”
    Elanco Animal Health President and CEO Jeff Simmons said, “Following a robust process over the last year, Merck Animal Health emerged as the right strategic buyer for the aquaculture business.
  • In March 2019, Merck Animal Health acquired Scan Aqua AS, a fish health and fish welfare company based in Norway, focused on key aqua products.

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Retrieved on: 
Giovedì, Febbraio 1, 2024
MSD, Security (finance), ADS, GHI, Prospectus, American depositary receipt, Merck, 3rd Floor, Sale, Merck & Co., Form

The closing of the offering is expected to occur on or about February 5, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about February 5, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be $15 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering is made only by means of a prospectus forming a part of the effective registration statement relating to the offering.
  • A preliminary prospectus relating to the offering has been filed with the SEC and a final prospectus relating to the offering will be filed with the SEC.

AUBERGE RESORTS COLLECTION ANNOUNCES STRATEGIC PARTNERSHIP WITH BDT & MSD PARTNERS

Retrieved on: 
Giovedì, Febbraio 1, 2024
MSD, Partnership, Growth, Life, BDT, Collection, Gulf States Toyota Distributors, Investment, Dan Friedkin

MILL VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- The Friedkin Group announced today that the company has entered into a strategic partnership with BDT & MSD Partners ("BDT & MSD"), a merchant bank built to serve the distinct needs of business owners and strategic, long-term investors. BDT & MSD, through its affiliated hospitality investment vehicle, will make a minority investment in Auberge Resorts Collection, the manager of the award-winning portfolio of luxury hotels, resorts, residences and private clubs set in some of the world's most desirable locations. In addition, BDT & MSD's hospitality vehicle intends to invest significant capital towards acquiring and developing luxury hotel and residential assets that will be branded and managed by Auberge Resorts Collection.

Key Points: 
  • MILL VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- The Friedkin Group announced today that the company has entered into a strategic partnership with BDT & MSD Partners ("BDT & MSD"), a merchant bank built to serve the distinct needs of business owners and strategic, long-term investors.
  • BDT & MSD, through its affiliated hospitality investment vehicle, will make a minority investment in Auberge Resorts Collection , the manager of the award-winning portfolio of luxury hotels, resorts, residences and private clubs set in some of the world's most desirable locations.
  • In addition, BDT & MSD's hospitality vehicle intends to invest significant capital towards acquiring and developing luxury hotel and residential assets that will be branded and managed by Auberge Resorts Collection.
  • The partnership reflects BDT & MSD's belief in Auberge Resorts Collection's unique brand positioning and focus on creating one-of-a-kind luxury hospitality experiences.

AUBERGE RESORTS COLLECTION ANNOUNCES STRATEGIC PARTNERSHIP WITH BDT & MSD PARTNERS

Retrieved on: 
Giovedì, Febbraio 1, 2024
MSD, Partnership, Growth, Life, BDT, Collection, Gulf States Toyota Distributors, Investment, Dan Friedkin

MILL VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- The Friedkin Group announced today that the company has entered into a strategic partnership with BDT & MSD Partners ("BDT & MSD"), a merchant bank built to serve the distinct needs of business owners and strategic, long-term investors. BDT & MSD, through its affiliated hospitality investment vehicle, will make a minority investment in Auberge Resorts Collection, the manager of the award-winning portfolio of luxury hotels, resorts, residences and private clubs set in some of the world's most desirable locations. In addition, BDT & MSD's hospitality vehicle intends to invest significant capital towards acquiring and developing luxury hotel and residential assets that will be branded and managed by Auberge Resorts Collection.

Key Points: 
  • MILL VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- The Friedkin Group announced today that the company has entered into a strategic partnership with BDT & MSD Partners ("BDT & MSD"), a merchant bank built to serve the distinct needs of business owners and strategic, long-term investors.
  • BDT & MSD, through its affiliated hospitality investment vehicle, will make a minority investment in Auberge Resorts Collection , the manager of the award-winning portfolio of luxury hotels, resorts, residences and private clubs set in some of the world's most desirable locations.
  • In addition, BDT & MSD's hospitality vehicle intends to invest significant capital towards acquiring and developing luxury hotel and residential assets that will be branded and managed by Auberge Resorts Collection.
  • The partnership reflects BDT & MSD's belief in Auberge Resorts Collection's unique brand positioning and focus on creating one-of-a-kind luxury hospitality experiences.